Published 1 September 2008, doi:10.1136/bmj.a1198
Cite this as: BMJ 2008;337:a1198

Research

Low dose aspirin and cognitive function in middle aged to elderly adults: randomised controlled trial

¹ Division of Community Health Sciences and Centre for Public Health and Primary Care Research, University of Edinburgh, Edinburgh, ² Psychology in the School of Philosophy, Psychology and Language, University of Edinburgh, ³ Department of Clinical Neurosciences, University of Edinburgh

Objective To determine the effects of low dose aspirin on cognitive function in middle aged to elderly men and women at moderately increased cardiovascular risk.

Design Randomised double blind placebo controlled trial.

Setting Central Scotland.

Participants 3350 men and women aged over 50 participating in the aspirin for asymptomatic atherosclerosis trial.

Intervention Low dose aspirin (100 mg daily) or placebo for five years.

Main outcome measures Tests of memory, executive function, non-verbal reasoning, mental flexibility, and information processing five years after randomisation, with scores used to create a summary cognitive score (general factor).

Results At baseline, mean vocabulary scores (an indicator of previous cognitive ability) were similar in the aspirin (30.9, SD 4.7) and placebo (31.1, SD 4.7) groups. In the primary intention to treat analysis, there was no significant difference at follow-up between the groups in the proportion achieving over the median general factor cognitive score (32.7% and 34.8% respectively, odds ratio 0.91, 95% confidence interval 0.79 to 1.05, P=0.20) or in mean scores on the individual cognitive tests. There were also no significant differences in change in cognitive ability over the five years in a subset of 504 who underwent detailed cognitive testing at baseline.

Conclusion Low dose aspirin does not affect cognitive function in middle aged to elderly people at increased cardiovascular risk.

Trial registration ISRCTN 66587262.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    StumbleUpon    Technorati    What's this?

Relevant Articles

Using aspirin to prevent cognitive decline

John W Eikelboom and Martin O’Donnell
BMJ 2008 337: a958. [Extract] [Full Text]

Low dose aspirin and cognitive function in the women's health study cognitive cohort

Jae Hee Kang, Nancy Cook, JoAnn Manson, Julie E Buring, and Francine Grodstein
BMJ 2007 334: 987. [Abstract] [Full Text] [PDF]

For Debate: Preventing atherosclerotic events with aspirin

John G F Cleland
BMJ 2002 324: 103-105. [Extract] [Full Text] [PDF]

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

Antithrombotic Trialists' Collaboration
BMJ 2002 324: 71-86. [Abstract] [Full Text] [PDF]

Cardiovascular disease and distribution of cognitive function in elderly people: the Rotterdam study

M M B Breteler, J J Claus, D E Grobbee, and A Hofman
BMJ 1994 308: 1604-1608. [Abstract] [Full Text]

This article has been cited by other articles:

• Marioni, R. E., Stewart, M. C., Murray, G. D., Deary, I. J., Fowkes, F. G. R., Lowe, G. D. O., Rumley, A., Price, J. F. (2009). Peripheral Levels of Fibrinogen, C-Reactive Protein, and Plasma Viscosity Predict Future Cognitive Decline in Individuals Without Dementia. Psychosom. Med. 71: 901-906 [Abstract] [Full text]  
• Bowler, J. V., Gorelick, P. B. (2009). Advances in Vascular Cognitive Impairment. Stroke 40: e315-e318 [Full text]  
• Strachan, M. W. J., Reynolds, R. M., Frier, B. M., Mitchell, R. J., Price, J. F. (2008). The relationship between type 2 diabetes and dementia. Br Med Bull 88: 131-146 [Abstract] [Full text]  
• (2008). Aspirin Does Not Affect Cognitive Function in People at Moderate CV Risk. JWatch General 2008: 3-3 [Full text]  
• Eikelboom, J. W, O'Donnell, M. (2008). Using aspirin to prevent cognitive decline. BMJ 337: a958-a958 [Full text]  

Online poll

Find out more on doc2doc >>